PubRank

ROS1 Targeting With Crizotinib in Advanced E-cadherin Negative, ER Positive Lobular Breast Cancer or Diffuse Gastric Cancer Study (ROLo)

Clinical Trial ID NCT03620643

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT03620643

Top papers

Rank Title Journal Year PubWeight™‹?›
1 First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014 10.91
2 Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010 8.55
3 Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 2014 6.95
4 Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010 3.88
5 Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene 2008 3.63
6 MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 2011 3.27
7 Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 2005 2.39
8 Lobular and ductal carcinomas of the breast have distinct genomic and expression profiles. Oncogene 2008 1.44
9 Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst 2013 1.28
10 Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge. World J Gastroenterol 2015 1.17
11 The role of the E-cadherin gene (CDH1) in diffuse gastric cancer susceptibility: from the laboratory to clinical practice. Ann Oncol 2003 1.17
12 Lobular breast cancer: molecular basis, mouse and cellular models. Breast Cancer Res 2015 0.91
13 Synthetic Lethal Screens Identify Vulnerabilities in GPCR Signaling and Cytoskeletal Organization in E-Cadherin-Deficient Cells. Mol Cancer Ther 2015 0.79
14 Tumor MET Expression and Gene Amplification in Chinese Patients with Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer. Mol Cancer Ther 2015 0.76
Next 100